Improved Production of Spores and Bioactive Metabolites from Bacillus amyloliquefaciens in Solid-state Fermentation by a Rapid Optimization Process

Probiotics and Antimicrobial Proteins - A dipicolonic acid fluorimetry assay was used instead of plate counting for the assessment of spore yields for enhanced optimization efficiency. The...     

河南省2013年风疹流行病学特征分析

目的了解河南省2013年风疹的流行病学特征,为制定风疹的防治策略提供参考依据。方法对河南省2013年风疹发病资料进行流行病学分析。结果 2013年河南省共报告风疹病例352例,无死亡病例。年均发病率为0.37/10万,其中以信阳市最高,郑州市次之,漯河市最低;发病主要集中在<15岁人群(80.40%),并以散居儿童和学生为主,男女性别比为1.61∶1;发病呈现明显的季节性,3—6月为发病高峰。结论河南省风疹发病率处于较低水平,<15岁儿童为主要发病人群。应提高重点人群风疹疫苗的接种率,预防风疹暴发,减少先天性风疹综合征的发生。     

HOCl causes necrotic cell death in human monocyte derived macrophages through calcium dependent calpain activation

The abundance of dead macrophages in close proximity to HOCl-modified proteins in advanced atherosclerotic plaques implicates HOCl in the killing of macrophages and the formation of the necrotic core region. The mechanism of HOCl mediated death of macrophages was unknown, so using human monocyte derived macrophages (HMDM) we here have shown that HOCl causes a rapid necrotic cell death characterized by loss of MTT reduction, cellular ATP and cell lysis without caspase-3 activation in HMDM cells. The HOCl causes a rise in cytosolic calcium level via the plasma membrane L- and T-type calcium channels and endoplasmic reticulum RyR channel. Blocking of the calcium channels or the addition of calpain inhibitors prevents the HOCl mediated loss of mitochondrial potential, lysosome failure and HMDM cell death. Blocking MPT-pore formation with cyclosporin A also prevents the loss of mitochondrial membrane potential, lysosomal destabilization and HMDM cell death. Blocking the calcium mitochondrial uniporter with ruthenium red also blocks the loss of mitochondrial potential but only at high concentrations. HOCl appears to cause HMDM cell death through destabilization of cytosolic calcium control resulting in the failure of both the mitochondria and lysosomes.     

表达全人源抗人IgE单抗的细胞株构建及筛选

目的:构建及筛选高效表达原创性全人源抗人Ig E单克隆抗体的重组工程细胞株。方法:将采用核糖体展示技术筛选到的原创性全人源抗人Ig E单链抗体(sc Fv)基因改构设计为Ig G1κ型全长抗体,构建重组真核表达质粒并电转染CHO-S细胞,Dot-blot法选取多株高表达克隆进行40ml摇瓶批次培养,再据细胞生长特征及抗体表达量选取高表达克隆进行40ml摇瓶及3L摇瓶流加培养研究,选取候选细胞株并对改构前后抗体的生物学活性进行比较研究。结果:成功构建了p MH3-H、p MH3-L、p CApuro-H、p CApuro-L四种重组真核表达质粒并成功共转染CHO-S细胞。完成了4次电转染8轮细胞克隆筛选,获得两株表达量较高的候选克隆Mab1#和Mab2#,在3L摇瓶流加培养中抗体表达量分别达到470mg/L及499mg/L。生物膜光干涉技术(Bio-Layer Interferometry,BLI)亲和力结果显示Mab1#及Mab2#两株单抗亲和力均达到nmol/L级(10-9),与现有唯一上市的抗人Ig E单抗药物奥马珠单抗(Omalizumab)的亲和力相当。选取Mab1#全长抗体与其改构前的母本单链抗体的表面等离子共振技术(surface plasmon resonance,SPR)中和活性比较结果显示Mab1#抑制h Ig E与FcεRI结合的EC50为3nmol/L,EC90为9nmol/L,较改造前亲和力提高了4.3倍,中和活性(EC50)提高了23.7倍,中和活性(EC90)提高了41.3倍。结论:成功将表达原创性全人源抗人Ig E的单链抗体(约25k Da)改造为亲和力及中和活性均大幅提升的全长抗体(约150k Da),获得2个候选细胞株。     

河南省2009—2013年流行性腮腺炎流行病学特征分析

了解河南省2009—2013年流行性腮腺炎的流行病学特征及规律,为制定流行性腮腺炎的预防控制措施提供参考依据。方法对河南省2009年1月1日至2013年12月31日通过"传染病报告信息管理系统"网络直报系统获得的流行性腮腺炎个案资料进行描述性流行病学分析。结果 2009—2013年河南省累计报告流行性腮腺炎病例91 822例,年均发病率为19.50/10万,男女发病比为1.95∶1(男性60 699例,女性31 123例),14岁以下年龄组发病率较高,年均发病率为88.99/10万,学生是主要的发病人群;流行性腮腺炎冬春季节多发,疾病流行呈现双峰分布;每年均有暴发疫情报告,多为学校内暴发。结论 2013年河南省年流行性腮腺炎发病率呈现下降趋势。暴发疫情起数和病例数波动较大,学校及托幼机构是流行性腮腺炎暴发流行的主要场所,应加强冬春季节学校及托幼机构流行性腮腺炎疫情的预防与控制,做好腮腺炎疫苗接种工作。     

The cell growth suppressor, mir-126, targets IRS-1

miRNAs are a family of approximately 22-nuleotide-long noncoding RNAs involved in the formation and progress of tumors. Since traditional methods for the detection of miRNAs expression have many disadvantages, we developed a simple method called polyA RT PCR. With this method, we detected a series of miRNAs and found that mir-126 is one of the miRNAs underexpressed in breast cancer cells. Flow cytometry analysis showed that mir-126 inhibited cell cycle progression from G1/G0 to S. Further studies revealed that mir-126 targeted IRS-1 at the translation level. Knocking down of IRS-1 suppresses cell growth in HEK293 and breast cancer cell MCF-7, which recapitulates the effects of mir-126. In conclusion, we developed a simple method for high-throughput screening of miRNAs and found that mir-126, a cell growth suppressor, targets IRS-1.     

飞机草地上部分化学成分及其抑菌活性研究

为探究飞机草地上部分化学成分及其抑菌作用.采用正相硅胶、Sephadex LH-20等色谱方法,从飞机草乙酸乙酯提取物中得到10个化合物,根据1H NMR、13C NMR、MS波谱数据,分别鉴定为:5,6,7,4'-四甲氧基黄烷酮(1)、圣草素-7,4'-二甲醚(2)、5,7-二羟基-6,4'-二甲氧基黄酮(3)、二氢...     

HPLC检测肠灌流模型中PMP衍生化葡寡糖含量的方法学建立

目的:建立肠灌流模型中1-苯基-3-甲基-5-吡唑啉酮(PMP)衍生化葡寡糖含量的检测方法,并进行方法学考察.方法:采用HPLC法测定,色谱条件为,色谱柱:phenomenex C18(250×4.60mm,51μm);流动相:100mMNaAc/乙腈(梯度洗脱);流速:1.0mL·min,-1;紫外检测波长245nm;进样量:20μL;柱温:40℃.结果:PMP衍生化葡寡糖在此色谱条件下获得良好分离,肠灌流液、血浆样品及酚红对10种化合物的检测均无影响.结论:该方法准确可靠,重复性良好,为寡糖的吸收研究提供了技术支持.     

CAP方案联合艾迪注射液治疗晚期非小细胞肺癌的临床研究

摘要 目的：研究CAP方案联合艾迪注射液治疗晚期非小细胞肺癌的效果。方法：选择2016年1月～2019年1月我院的81例晚期非小细胞肺癌患者,随机分为两组。对照组的41例晚期非小细胞肺癌患者采用CAP方案,即快速静脉滴注吡柔比星50 mg/m²和环磷酰胺600 mg/m²,d1,顺铂80 mg/m²,d2-d4,1 个周期为28 d,共治疗2个周期。观察组的40例晚期非小细胞肺癌患者联合静脉滴注艾迪注射液,每次50 mL,每天1次,1个疗程为3 w,共治疗3个疗程。比较两组的免疫功能、生活质量和不良反应情况。结果：观察组的有效率明显高于对照组(P<0.05）;观察组治疗后的CD4⁺、CD3⁺及CD4⁺/CD8⁺明显升高(P<0.05）,且明显高于对照组(P<0.05）;观察组的生活质量提高17例,稳定10例,降低6例,观察组的生活质量改善率为82.50%（33/40）,明显高于对照组的53.66%（22/41）(P<0.05）;观察组的消化道反应发生率明显低于对照组(P<0.05）,两组的过敏反应、神经毒性和脱发发生率无明显差异(P>0.05）。结论：艾迪注射液联合CAP方案可以提高晚期非小细胞肺癌的化疗疗效以及生活质量,改善免疫功能,减轻化疗所致的不良反应。     

Osteoprotective Effect of Echinocystic Acid,a Triterpone Component from Eclipta prostrata,in Ovariectomy-Induced Osteoporotic Rats

Echinocystic acid (EA) is a natural triterpone enriched in various herbs and has been used for medicinal purposes in China. In the present study, we systematically examined the effects of EA on ovariectomy-induced osteoporosis in rats for the first time. Three-month-old female ovariectomy (OVX) Sprague–Dawley rats were used to evaluate the osteoprotective effect of EA. Results showed that administration of EA (5 or 15 mg/kg/day) for 12 weeks prevented lower levels of maximum stress and Young’s modulus of femur induced by OVX. EA also recovered bone metabolic biomarkers levels in OVX rats, including osteocalcin, alkaline phosphatese, deoxypyridinoline, and urinary calcium and phosphorus. EA (5 and 15 mg/kg/day) could prevent the alteration of total bone mineral density in the femur caused by OVX. However, only high dose (15 mg/kg/day) of EA significantly improved trabecular architecture, as evidenced by higher levels of bone volume/tissue volume, trabecula number, and trabecula thickness, and lower levels of trabecula separation and structure model index compared with OVX rats. In addition, EA treatment decresed the serum levels of IL-1β and TNF-α in OVX rats. In conclusion, EA could prevent reduction of bone mass and strength and improve the cancellous bone structure and biochemical properties in OVX rats. Hence, EA may serve as a new candidate or a leading compound for anti-osteoporosis.